

November 20, 2024

Company: Chiome Bioscience Inc.

Representative: Shigeru Kobayashi, President & CEO

(Code: 4583, Tokyo Stock Exchange Growth)

## **Chiome Announces Exclusive Licensing Agreement for Anti-CX3CR1 Antibody**

Chiome Bioscience Inc. (“Chiome”) and Asahi Kasei Pharma Corporation (Headquarters: Chiyoda-ku, Tokyo, President: Yoshikazu Aoki, “Asahi Kasei Pharma”) today announced conclusion of an exclusive license agreement for humanized anti-CX3CR1 antibody (our project code: PFKR).

Under the terms of the agreement, Chiome grants Asahi Kasei Pharma worldwide rights with sublicensing privileges for the development, manufacturing and commercialization of PFKR. Chiome will receive ¥200 million as the upfront payment and is eligible to receive up to ¥24.8 billion in total of development milestones payments and sales milestones, plus sales-based royalty after the product launch.

We believe that our licensing agreement with Asahi Kasei Pharma will help maximize the value of PFKR and speed up its development and commercialization.

Upfront payments received upon the conclusion of this agreement will be recorded as net sales for the drug discovery business in the fourth quarter of the fiscal year ending December 31, 2024. We will promptly disclose any items that require disclosure in the future.

### <Asahi Kasei Pharma Corporation>

In accordance with the Asahi Kasei Pharma Mission of “to sincerely care for each individual life and solve their unmet medical needs with a wealth of ideas and solid science”, Asahi Kasei Pharma operates pharmaceutical and diagnostic businesses in the Health Care Business Unit of the Asahi Kasei Group. Asahi Kasei Pharma has developed numerous innovative drugs in the field of immunology and rare diseases, contributing to society by providing such products to patients who suffer from diseases.

To learn more - [https:// www.asahi-kasei.co.jp/pharma/en](https://www.asahi-kasei.co.jp/pharma/en)

### <PFKR>

PFKR is a humanized anti-CX3CR1 antibody for CX3CR1, a type of G-protein-coupled receptor (GPCR). It was obtained by Chiome in the joint research program with the National Center of Neurology and Psychiatry (“NCNP”).

This antibody inhibits the binding between CX3CR1 and Fractalkine, which results in inhibition of migration of the immune cells to inflammatory sites. The international patent application for our research results on this antibody, in collaboration with NCNP, was completed in 2023.

### [Inquiries]

Chiome Bioscience Inc. Investor Relations

E-mail: [ir@chiome.co.jp](mailto:ir@chiome.co.jp)